The FDA has approved a higher 7.2 mg dose of Novo Nordisk’s Wegovy (Wegovy HD) for chronic weight management in adults with ...

About 10 weeks after it was approved, the Wegovy pill is now estimated to be part of the daily regimen of about 400,000 Americans. And the field of weight-loss treatment is on the verge of even more ...

Doctors explain the differences between the Wegovy pill and injection in terms of efficacy, side effects, and more. They ...

Data from the phase 3b STEP UP trial demonstrate that the 7.2 mg semaglutide dose provides superior weight reduction compared ...

The name "Ozempic 2.0" has been floating around on various outlets and on social media, as a trending nickname for the next generation of weight loss drugs that are in the works for 2026. Both Eli ...

Novo Nordisk said it plans to launch the new formulation, (semaglutide 7.2 mg), in the United States in April 2026.

With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.